

# GUIDELINES ON HEPATITIS B AND C TESTING

FEBRUARY 2017

GUIDELINES



# **GUIDELINES ON HEPATITIS B AND C TESTING**

FEBRUARY 2017

WHO guidelines on hepatitis B and C testing

ISBN 978-92-4-154998-1

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in China

Design and layout: [blossoming.it](http://blossoming.it)

# CONTENTS

<b>ACKNOWLEDGEMENTS</b>	<b>x</b>
<b>ABBREVIATIONS AND ACRONYMS</b>	<b>xiv</b>
<b>GLOSSARY OF TERMS</b>	<b>xvi</b>
<b>EXECUTIVE SUMMARY</b>	<b>xxi</b>
<b>SUMMARY ALGORITHMS</b>	<b>xxvi</b>
<b>SUMMARY OF RECOMMENDATIONS</b>	<b>xxvii</b>
<b>PART 1: BACKGROUND</b>	<b>1</b>
<b>1. INTRODUCTION</b>	<b>2</b>
1.1. Current challenges in viral hepatitis testing	2
1.2. Goals of viral hepatitis testing	3
1.3. Why are testing guidelines needed?	4
1.4. Goals and objectives of the guidelines	5
1.5. Scope of the guidelines	5
1.6. Target audience	6
1.7. Related WHO materials and guidelines	6
<b>2. GUIDING PRINCIPLES</b>	<b>8</b>
2.1. Promoting human rights and equity in access to hepatitis testing	8
2.2. The public health approach along the continuum of care	8
2.3. The WHO “5 Cs”	9
2.4. Accurate testing	9
<b>3. METHODOLOGY AND PROCESS OF DEVELOPING THE GUIDELINES</b>	<b>10</b>
3.1. WHO guideline development process	10
3.2. Systematic reviews and additional background work	10
3.3. Grading of quality of evidence and strength of recommendations	11
3.4. Formulation of recommendations	14
3.5. Declaration and management of conflicts of interest	15
3.6. Updating, disseminating and monitoring implementation of the guidelines	15
<b>4. BACKGROUND – EPIDEMIOLOGY AND NATURAL HISTORY</b>	<b>16</b>
<b>4.1. Hepatitis B infection</b>	<b>19</b>
4.1.1. Epidemiology of hepatitis B infection	19
4.1.2. Transmission of hepatitis B infection	20
4.1.3. Natural history of HBV infection	20
4.1.4. Time course and interpretation of serological markers of HBV infection	21
4.1.5. Preventing hepatitis B infection through vaccination	24
4.1.6. Treatment of hepatitis B infection	24

4.2.	<b>Hepatitis C infection</b>	24
4.2.1.	Epidemiology of hepatitis C infection	24
4.2.2.	Transmission of hepatitis C infection	25
4.2.3.	Natural history of hepatitis C infection	27
4.2.4.	Time course of serological markers for HCV infection	27
4.2.5.	Prevention of hepatitis C infection	28
4.2.6.	Treatment of hepatitis C infection	28
<b>5.</b>	<b>BACKGROUND – DIAGNOSTICS FOR TESTING FOR HEPATITIS B AND C INFECTION</b>	<b>30</b>
5.1.	Types of viral hepatitis assays	30
5.2.	Serological assays	30
5.3.	Nucleic acid testing (NAT) technologies	31
5.4.	Choice of serological assays	32
5.5.	Selection of a one or two assay serological testing strategy	32
	<b>PART 2: RECOMMENDATIONS</b>	<b>35</b>
<b>6.</b>	<b>WHO TO TEST FOR CHRONIC HEPATITIS B OR C INFECTION</b>	
	– testing approaches and service delivery	<b>36</b>
6.1.	Recommendations	36
6.2.	Background	38
<b>6A</b>	<b>TESTING APPROACHES TO DETECT CHRONIC HEPATITIS B</b>	<b>40</b>
6.3.	Summary of the evidence	40
6.4.	Rationale for the recommendations	41
<b>6B</b>	<b>TESTING APPROACHES TO DETECT CHRONIC HEPATITIS C</b>	<b>45</b>
6.5.	Summary of the evidence	45
6.6.	Rationale for the recommendations	46
<b>6C</b>	<b>SERVICE DELIVERY OF HEPATITIS B AND C TESTING</b>	<b>49</b>
6.7.	Rationale for the recommendations on community-based testing	49
6.8.	Rationale for the recommendations on facility-based testing	50
6.9.	Implementation considerations for HBV and HCV testing approaches	51
<b>7.</b>	<b>HOW TO TEST FOR CHRONIC HEPATITIS B INFECTION</b>	
	– choice of serological assay and testing strategy	<b>52</b>
7.1.	Recommendations	52
7.2.	Background	53
7.3.	Summary of the evidence	54
7.4.	Rationale for the recommendations on which assay to use	57
7.5.	Rationale for the recommendations on testing strategy	59

<b>8. HOW TO TEST FOR CURRENT OR PAST HCV INFECTION (HCV EXPOSURE)</b>	<b>61</b>
– choice of serological assay and testing strategy	
8.1. Recommendations	61
8.2. Background	62
8.3. Summary of the evidence	62
8.4. Rationale for the recommendations on which assay to use	65
8.5. Rationale for the recommendation for a one-serological assay testing strategy	67
8.6. Implementation considerations for HBsAg and HCV antibody serological testing	68
<b>9. DETECTION OF VIRAEMIC HBV INFECTION – to guide who to treat or not treat</b>	<b>70</b>
9.1. Recommendation	70
9.2. Background	72
9.3. Rationale for the recommendations (WHO 2015 HBV guidelines)	72
9.4. Implementation considerations	73
<b>10. MONITORING FOR HBV TREATMENT RESPONSE AND DISEASE PROGRESSION</b>	<b>74</b>
10.1. Recommendations	74
10.2. Background – goals of monitoring	74
10.3. Rationale for the recommendations (WHO 2015 HBV guidelines )	75
10.4. Implementation considerations	76
<b>11. DETECTION OF VIRAEMIC HCV INFECTION – to guide who to treat</b>	<b>77</b>
11.1. Recommendations	77
11.2. Background	77
11.3. Summary of the evidence	78
11.4. Rationale for the recommendations	80
11.5. Implementation considerations	81
<b>12. ASSESSMENT OF HCV TREATMENT RESPONSE</b>	<b>83</b>
12.1. Recommendation	83
12.2. Background	83
12.3. Summary of the evidence	83
12.4. Rationale for the recommendations	84
12.5. Implementation considerations	85
<b>13. USE OF DRIED BLOOD SPOT SPECIMENS FOR SEROLOGICAL AND VIROLOGICAL TESTING</b>	<b>86</b>
13.1. Recommendations	86
13.2. Background	86
13.3. Summary of the evidence	87
13.4. Rationale for the recommendations	89
13.5. Implementation considerations	92

<b>14. IMPROVING THE UPTAKE OF TESTING AND LINKAGE TO CARE AND PREVENTION</b>	<b>95</b>
14.1. Recommendations	95
14.2. Background	95
14.3. Summary of the evidence	96
14.4. Rationale for the recommendations	98
14.5. Implementation considerations	100
<b>PART 3: IMPLEMENTATION</b>	<b>101</b>
<b>15. IMPLEMENTING LABORATORY TESTING SERVICES FOR VIRAL HEPATITIS</b>	<b>102</b>
15.1. Key elements for national testing services	102
15.2. National framework for viral hepatitis testing	103
15.3. Building capacity for testing services	104
15.4. Product selection	106
15.5. Assuring the quality of testing services	109
15.6. Assuring the safety of testing services	111
15.7. Other practical considerations for testing	111
<b>16. PRE-TEST AND POST-TEST COUNSELLING</b>	<b>114</b>
16.1. Promoting testing awareness	114
16.2. Creating an enabling environment	115
16.3. The WHO 5 “Cs”	115
16.4. Providing pre-test information	116
16.5. Post-test counseling and services	117
<b>17. SERVICE DELIVERY APPROACHES TO VIRAL HEPATITIS TESTING – examples from the field</b>	<b>119</b>
17.1. Health-care facility-based testing	120
17.2. Community-based testing	123
17.3. Good practices for delivery of effective viral hepatitis testing services	127
17.4. Diagnostic innovations to promote access to testing	130
<b>18. TESTING ISSUES IN SPECIFIC POPULATIONS</b>	<b>132</b>

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26564](https://www.yunbaogao.cn/report/index/report?reportId=5_26564)

